NEUBASE THERAPEUTICS INC (NBSE)
US64132K2015 - Common Stock
ChartMill assigns a Buy % Consensus number of 43% to NBSE. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 142.8. This target is 37677.78% above the current price.
NBSE was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about NBSE.
In the previous month the buy percentage consensus was at a similar level.
NBSE was analyzed by 6 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-10-21 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2022-10-18 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2022-10-17 | Chardan Capital | Downgrade | Buy -> Neutral |
| 2022-08-12 | Chardan Capital | Maintains | Buy |
| 2022-05-31 | HC Wainwright & Co. | Maintains | Buy |
| 2022-05-13 | Chardan Capital | Maintains | Buy |
| 2021-06-01 | HC Wainwright & Co. | Maintains | Buy |
| 2021-02-12 | HC Wainwright & Co. | Maintains | Buy |